{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:48:06Z","timestamp":1788526086264,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Botulinum toxin A (BoNT-A) is widely used in the treatment of neurological disorders. Despite guideline recommendations, particularly regarding BoNT-A injections for post-stroke spasticity, current evidence shows that many patients in Germany do not receive BoNT-A therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An analysis of travel time to neurological Botulinum Toxin (BoNT-A) centers was conducted based on German hospital quality reports. Additionally, the German Botulinum Toxin Working Group (Arbeitskreis Botulinumtoxin e. V.; AK-BoNT) performed an anonymous online survey of its members, who treat with BoNT, between November 2023 and March 2024 to document experiences, identify perceived barriers, and explore potential improvements in BoNT-A therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The geospatial analysis showed theoretical accessibility to specialized neurological BoNT\u2212A centers in Germany with 96.72% of the population residing within a 60-min drive of a qualified facility. Of 632 invited AK-BoNT members, 191 completed the survey in full (30.2% response rate). 79.6% of the respondents worked in neurology and two thirds of the respondents had more than 10 years of experience with BoNT-A. Although more than 60% of respondents rated BoNT-A therapy as effective regardless of indication, many pointed to structural and economic barriers, including inadequate reimbursement pathways and limited multidisciplinary collaboration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results indicate that BoNT-A is recognized and provides therapeutic benefit from the perspective of the treating physician, but structural and economic barriers hinder the use of this therapy. Interestingly, even in a well-resourced system with broad geographic access to specialized care, significant treatment gaps may persist. Recommendations include standardized reimbursement structures, improved education, and increased cross-sector collaboration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1715279","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:34:11Z","timestamp":1771392851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mind the gap: a German case study on the discrepancy between geographic accessibility and real-world utilization of botulinum toxin therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Tristan","family":"Koelsche","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Masanneck","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Ih","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]},{"name":"Department of Neurology and Neurophysiology, GFO Clinics Rhein-Berg","place":["Bergisch Gladbach, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]},{"name":"Department of Neurology, Kliniken Maria Hilf","place":["M\u00f6nchengladbach, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ncl.2020.09.01","article-title":"An update on botulinum toxin in neurology","volume":"39","author":"Chiu","year":"2021","journal-title":"Neurol Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/toxins16020098","article-title":"Best practice guidelines for the management of patients with post-stroke spasticity: a modified scoping review","volume":"16","author":"Suputtitada","year":"2024","journal-title":"Toxins"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00115-023-01571-8","article-title":"Improvement of the treatment of patients with spastic movement disorder after stroke","volume":"95","author":"Lee","year":"2024","journal-title":"Nervenarzt"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/20552076231152989","article-title":"Driving time-based identification of gaps in specialised care coverage: an example of neuroinflammatory diseases in Germany","volume":"9","author":"Masanneck","year":"2023","journal-title":"Digit Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3238\/arztebl.m2023.0149","article-title":"A study of the geographic accessibility of outpatient memory clinics in Germany","volume":"120","author":"Masanneck","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"ref6","volume-title":"GHS-POP R2023A - GHS population grid multitemporal (1975-2030)","year":"2023"},{"key":"ref7","volume-title":"SoSci Survey (Version 3.5.02)","author":"Leiner","year":"2024"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s10072-023-06693-0","article-title":"Botulinum toxin in clinical practice: state of the art of administration provisions in Italy","volume":"44","author":"Marano","year":"2023","journal-title":"Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/a-1671-5856","article-title":"Botulinumtoxin in der neurologischen Praxis in Deutschland","volume":"53","author":"Raffauf","year":"2022","journal-title":"Klin Neurophysiol"},{"key":"ref10","volume-title":"Therapie des spastischen Syndroms Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie Herausgegeben von der Deutschen Gesellschaft f\u00fcr Neurologie (DGN) und der Deutschen Gesellschaft f\u00fcr Neurorehabilitation (DGNR) unter Mitwirkung der am Konsensusprozess beteiligten Fachgesellschaften, Berufsverb\u00e4nde und Organisationen","author":"Platz","year":"2025"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"107150","DOI":"10.1016\/j.toxicon.2023.107150","article-title":"Early versus late injections of Botulinumtoxin type a in post-stroke spastic movement disorder: a literature review","volume":"229","author":"Wissel","year":"2023","journal-title":"Toxicon"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/a-1896-2057","article-title":"Pr\u00e4valenz und medikament\u00f6se Behandlungsstrategie des spastischen Syndroms in Deutschland \u2013 Eine Retrospektive Analyse von Abrechnungsdaten der gesetzlichen Krankenversicherung","volume":"28","author":"Katzenmeyer","year":"2023","journal-title":"Gesundheits\u00f6konomie Qualit\u00e4tsmanagement"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3238\/arztebl.m2023.0004","article-title":"The incidence and outpatient medical care of patients with post-stroke spasticity","volume":"120","author":"Rakers","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"101869","DOI":"10.1016\/j.rehab.2024.101869","article-title":"Short- medium- and long-term effects of botulinum toxin on upper limb spasticity in children with cerebral palsy: a meta-analysis of randomized controlled trials","volume":"67","author":"Chen","year":"2024","journal-title":"Ann Phys Rehabil Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"CD004899","DOI":"10.1002\/14651858.CD004899.pub3","article-title":"Botulinum toxin type a therapy for hemifacial spasm","volume":"2020","author":"Duarte","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"CD003633","DOI":"10.1002\/14651858.CD003633.pub4","article-title":"Botulinum toxin type a therapy for cervical dystonia","volume":"2020","author":"Rodrigues","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pmrj.13211","article-title":"AAPM&R consensus guidance on spasticity assessment and management","volume":"16","author":"Verduzco-Gutierrez","year":"2024","journal-title":"PM&R"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache report of the guideline development Subcommittee of the American Academy of neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/a-1802-6006","article-title":"Behandlung der Sialorrhoe mit Botulinum Neurotoxin Typ A \u2013 Konsentierte Praxisempfehlungen f\u00fcr Kinder und Erwachsene","volume":"90","author":"Jost","year":"2022","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e027953","DOI":"10.1136\/bmjopen-2018-027953","article-title":"Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine","volume":"9","author":"Herd","year":"2019","journal-title":"BMJ Open"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement","volume":"262","author":"Albanese","year":"2015","journal-title":"J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/14740338.2021.1915282","article-title":"Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal","volume":"20","author":"Marsili","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00784-024-05718-y","article-title":"A systematic review of the perspectives of botulinum toxin use on the quality of life of neurological patients with drooling","volume":"28","author":"Silva","year":"2024","journal-title":"Clin Oral Investig"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-024-03883-x","article-title":"Efficacy and safety of botulinum neurotoxin in the treatment of hemifacial spasms: a systematic review and meta-analysis","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-019-09527-2","article-title":"How satisfied are cervical dystonia patients after 3 years of botulinum toxin type a treatment? Results from a prospective, long-term observational study","volume":"266","author":"Colosimo","year":"2019","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1553989","DOI":"10.3389\/fneur.2025.1553989","article-title":"Do female and male patients with cervical dystonia respond differently to long-term botulinum neurotoxin therapy?","volume":"16","author":"Hefter","year":"2025","journal-title":"Front Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/wjo2.88","article-title":"Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia","volume":"9","author":"Heyes","year":"2023","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/toxins14040246","article-title":"An observational cross-sectional study of gender and disability as determinants of person-centered medicine in botulinum neurotoxin treatment of upper motoneuron syndrome","volume":"14","author":"Del Prete","year":"2022","journal-title":"Toxins"},{"key":"ref30","article-title":"(Muster-)Weiterbildungsordnung 2018","volume-title":"Munich: SoSci Survey GmbH","year":"2025"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00702-022-02494-5","article-title":"Botulinum toxin therapy: past, present and future developments","volume":"129","author":"Dressler","year":"2022","journal-title":"J Neural Transm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1212\/CPJ.0000000000000243","article-title":"Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache payment policy perspectives","volume":"6","author":"Govindarajan","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1007\/s00415-011-5998-9","article-title":"Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study","volume":"258","author":"Burbaud","year":"2011","journal-title":"J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1715279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:34:13Z","timestamp":1771392853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1715279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":33,"alternative-id":["10.3389\/fneur.2026.1715279"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1715279","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1715279"}}